Mashup Score:11
OncLiveDurvalumab Plus Chemo Significantly Improves OS in Frontline Advanced Biliary Tract Cancer - 16 hours
Mashup Score:11
Twitter Feed: OncLive.com
Mashup Score:9
OncLiveClinical Management of ROS1+ Advanced NSCLC - 13 hours
Mashup Score:9
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for...
-
WATCH: @benlevylungdoc, of @hopkinskimmel, Mark Socinski, of @AdventHealth, & @StephenVLiu, of @LombardiCancer, describe the treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1. #lcsm https://t.co/pkZHBAFUd4 https://t.co/pkZHBAFUd4 - view on twitter
More coverage:
#lcsm
Mashup Score:8
OncLiveA Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing - 2 days
Mashup Score:8
The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure...
-
A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing @StephenVLiu @LombardiCancer #lcsm https://t.co/TuF97dNHWA - view on twitter
More coverage:
#lcsm
Mashup Score:6
OncLiveAbid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients - 19 hours
Mashup Score:6
Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses,...
-
In a previous episode of #OncLiveOnAir, @BilalAbidMD, of @MedicalCollege, discusses immune-compromising factors in CAR T-cell therapy recipients and the immunogenic potential of different #COVID19 vaccines, determinants of vaccine responses. #oncology https://t.co/8Zay2gJz0P https://t.co/8Zay2gJz0P - view on twitter
Mashup Score:5
OncLivePlinabulin/Docetaxel Demonstrates Durable Antitumor Benefit in EGFR Wild-Type NSCLC - 1 day
Mashup Score:5
The addition of plinabulin to docetaxel demonstrated durable anticancer benefit in terms of overall survival when used in the second- or third-line treatment of...
-
Plinabulin + docetaxel demonstrated durable anticancer benefit when used in the 2nd- or 3rd-line treatment of patients w/ EGFR wild-type non–small cell lung cancer who had progressed on a prior platinum-based regimen. @PiedmontHealth @myESMO #ESMO21 #lcsm https://t.co/Lb430TDkv7 - view on twitter
Mashup Score:4
OncLiveLessons Learned May Hold the Key for Improving Outcomes in Fibrolamellar Carcinoma - 1 day
Mashup Score:4
Fibrolamellar carcinoma is an extremely rare form of liver cancer that affects approximately 1 in 5 million Americans. However, because the disease appears so...
-
Fibrolamellar carcinoma is a rare form of liver cancer that affects approximately 1 in 5 million Americans. However, because the disease appears so infrequently, it may be underdiagnosed. @MarkYarchoan @hopkinskimmel #oncology #MedTwitter #livercancer https://t.co/XN7iCbVnfM - view on twitter
Mashup Score:3
OncLiveDr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination - 1 day
Mashup Score:3
Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19...
-
WATCH: @BilalAbidMD, of @MedicalCollege, discusses the potential impact of CAR T-cell therapy on the efficacy of #COVID19 vaccinations. #oncology https://t.co/m0fCDje7Jw - view on twitter
Mashup Score:3
OncLiveThe European Commission has approved nivolumab plus fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with HER2-negative advanced or metastatic gastric,...
-
Based on data from the phase 3 CheckMate-649 trial, nivolumab + chemotherapy had a meaningful improvement in OS and PFS over chemotherapy alone in this patient population. @EU_Commission #esocsm https://t.co/IydorQmhXa https://t.co/IydorQmhXa - view on twitter
More coverage:
#esocsm
Mashup Score:3
OncLiveDr. Johnson on Datopotamab Deruxtecan in NSCLC With Actionable Genomic Alterations - 2 days
Mashup Score:3
Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic...
-
WATCH: @MLJohnsonMD2, of @SarahCannonDocs, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations. #lcsm https://t.co/23iYF4C5RG - view on twitter
More coverage:
#lcsm
Mashup Score:2
OncLiveIGHV Mutation Status Now Included in clonoSEQ Diagnostic Assay in CLL - 1 day
Mashup Score:2
An upgraded model of the clonoSEQ® B-cell Clonality diagnostic tool has been released, which will now include IGHV mutation status for patients with chronic...
-
RT @DrBonillaOnc: IGHV Mutation Status Now Included in clonoSEQ Diagnostic Assay in CLL https://t.co/dngh4AWTkm via @onclive - view on twitter
The combination of durvalumab and chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone when used...
Durvalumab Plus Chemo Significantly Improves OS in Frontline Advanced Biliary Tract Cancer #stomachcancer #oncology #MedTwitter https://t.co/1EaZLUrpet - view on twitter